Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and healthcare platform specializing in ...

The March 2026 issue of NEJM Catalyst Innovations in Care Delivery is a special theme issue on the hard work of implementing artificial intelligence in real-world ...

Sarcomas, a diverse group of malignancies, exhibit substantial heterogeneity in both biological behavior and microenvironment, influencing their response to immunotherapy. Although pembrolizumab is ...

• In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plusdarolutamide in men with metastatic castration resistant prostate cancer (“mCRPC”),the six-month radiographic ...

Content warning: This article contains references to suicide. The National Suicide Prevention Lifeline is a hotline for individuals in crisis or for those looking to help someone else. To speak with a ...

Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials National estimates of cancer ...

Preclinical in vitro studies demonstrated >80% reduction in protease activity, including complete inhibition of TACE and collagenase — key factors in non-healing chronic wounds revyve® data featured ...

A doctor from the University of Palermo in Italy has published a case study of an adult cocaine user who experienced reduced withdrawal symptoms when given GLP-1 therapy. In the case study published ...

Like reasoning in clinical practice, there may not be a single right answer when deciding what pedagogical approach to adopt. We developed an e-learning package for use as self-directed learning, to ...

The Case Comprehensive Cancer Center (Case CCC) is encouraging investigators to submit a project narrative for Early Phase Clinical Research Support (EPCRS) funding. These in-house funds are available ...